好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Traumatic Brain Injury (TBI) Severity and Radiographic Imaging in Primary Symptom of Post-TBI Headache
Neuro Trauma and Critical Care
S34 - Neuro Trauma and Sports Neurology (12:03 PM-12:15 PM)
005

To investigate the relationship between traumatic brain injury (TBI) severity, radiographic imaging findings, and post-traumatic headache (PTH) being reported as the most disabling symptom in a post-TBI clinic cohort.

Post-traumatic headache (PTH) is a common and debilitating condition following TBI, but its mechanisms are unclear. The roles of TBI severity and positive radiographic findings as risk factors for PTH being the primary disabling complaint remain unknown.

Retrospective cohort study of 170 sequential-clinic-TBI patients (09/22-09/25). PTH defined as the patient's self-reported headache being the most disabling symptom and fitting ICHD-3 criteria for acute (<3 months) or chronic (>3 months) PTH. TBI severity classified as mild TBI (mTBI) if GCS ≥13. Radiographic findings “positive” if any intracranial blood or skull fracture on head CT. Multivariable logistic regression, adjusted for covariates: age, sex, mechanism, and time to visit.

Of the 170 patients (mean age 46.88, 43.3% female, 74.9% mTBI, median-evaluation 5 months), 48 reported PTH as their most disabling symptom. Disabling PTH was more common in females (58.3% vs 41.7%, p=0.018), those seen <3 months post-TBI (54.2% vs 45.8%, p=0.028), blunt assault (54.2% vs 45.8%, p=0.019), patients with cervicogenic symptoms (47.9% vs 21.0%, p=0.003), and following mTBI (95.8% vs 4.2%, p<0.001). Multivariable analysis showed that patients with moderate-severe TBI (OR 0.09, 95% CI 0.03-0.25, p<0.001), positive radiographic findings (OR 0.21, CI 0.09-0.0.48, p<0.001), and evaluation >3 months (OR 0.38, CI 0.15-0.91, p=0.03) had lower odds of reporting disabling PTH.

Patients with more severe TBI and those with positive imaging findings paradoxically show lower rates of PTH reported as the most disabling symptom. Disabling headaches are also more common acutely than chronically. These findings suggest that the factors driving headache as the primary disabling complaint differ based on TBI severity. Future studies will explore the role of psychosocial factors.

Authors/Disclosures
Brandon Nguyen, MD (University of California, Irvine)
PRESENTER
Dr. Nguyen has nothing to disclose.
Amanda Fang, Undergraduate student Miss Fang has nothing to disclose.
Stephania B. Tovar Vargas, MPH Ms. Tovar Vargas has nothing to disclose.
Maral Sakayan, MD (UCI Department of Neurology) Dr. Sakayan has nothing to disclose.
Asia Walter Miss Walter has nothing to disclose.
Miranda Saathoff Mrs. Saathoff has nothing to disclose.
Danh V. Nguyen, PhD Prof. Nguyen has nothing to disclose.
Christopher Giza, MD, FAAN (UCLA, Depts of Pediatrics and Neurosurgery) Dr. Giza has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medical Network Speakers Bureau. Dr. Giza has stock in Highmark Interactive. The institution of Dr. Giza has received research support from UCLA: Brain Injury Research Center, Steve Tisch BrainSPORT Program, Easton Clinic for Brain Health. Dr. Giza has received publishing royalties from a publication relating to health care. Dr. Giza has a non-compensated relationship as a Advisory Board with Major League Soccer that is relevant to AAN interests or activities. Dr. Giza has a non-compensated relationship as a Advisory Board with National Basketball Association that is relevant to AAN interests or activities. Dr. Giza has a non-compensated relationship as a Consultant with United States Soccer Federation that is relevant to AAN interests or activities. Dr. Giza has a non-compensated relationship as a Co-founder & Advisor with Symptomwise that is relevant to AAN interests or activities.
Bernadette Boden-Albala, DrPH (University California Irvine) Ms. Boden-Albala has received research support from NIH.
Crystal Jicha, MD (UC Irvine) Dr. Jicha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LinPharma.
Nan Cheng, MD (UCI) Dr. Cheng has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie.
Dallas De La Vara, MD Dr. De La Vara has nothing to disclose.
Patrick M. Chen, MD (UC Irvine Medical Center) Dr. Chen has nothing to disclose.